Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BBEST02
- Development stage
- Preclinical
- Lead developer
- AMYRA Biotech
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Administration
- Oral
01
Overview
BBEST02 is an enzyme supplementation product candidate developed by AMYRA Biotech using its proprietary Brush Border Enzyme Supplementation Technology (BBEST). The product is designed to supplement or replace essential brush border enzymes that line the small intestine, which are often deficient or dysfunctional in individuals with various gastrointestinal conditions. By restoring these enzymatic activities, BBEST02 aims to improve the digestion of nutrients, mitigate food sensitivities, and manage symptoms associated with intestinal digestion disorders. It is currently positioned within AMYRA's consumer healthcare pipeline as a potential solution for improving nutritional uptake and gastrointestinal health.
02
Targets
Sucrase-Isomaltase
Beyond the preview
Go deeper on BBEST02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BBEST02.